Display options
Cite
Ninomiya H, Obara N, Niiori-Onishi A, et al. Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Rep Hematol. 2015;2015:673195doi: 10.1155/2015/673195.
Ninomiya, H., Obara, N., Niiori-Onishi, A., Yokoyama, Y., Sakata-Yanagimoto, M., Hasegawa, Y., & Chiba, S. (2015). Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case reports in hematology, 2015673195. https://doi.org/10.1155/2015/673195
Ninomiya, Haruhiko, et al. "Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria." Case reports in hematology vol. 2015 (2015): 673195. doi: https://doi.org/10.1155/2015/673195
Ninomiya H, Obara N, Niiori-Onishi A, Yokoyama Y, Sakata-Yanagimoto M, Hasegawa Y, Chiba S. Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Rep Hematol. 2015;2015:673195. doi: 10.1155/2015/673195. Epub 2015 Jun 01. PMID: 26124968; PMCID: PMC4466353.
Copy Download .nbib Format: NLM
Share it on

Case Rep Hematol. 2015;2015:673195. doi: 10.1155/2015/673195. Epub 2015 Jun 01.

Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria.

Case reports in hematology

Haruhiko Ninomiya, Naoshi Obara, Akiko Niiori-Onishi, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Yuichi Hasegawa, Shigeru Chiba

Affiliations

  1. Department of Medical Sciences, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.
  2. Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.
  3. Department of Internal Medicine, Hitachi, Ltd., Hitachinaka General Hospital, Hitachinaka 312-0057, Japan.

PMID: 26124968 PMCID: PMC4466353 DOI: 10.1155/2015/673195

Abstract

Chronic kidney disease (CKD) is one of the major manifestations of paroxysmal nocturnal hemoglobinuria (PNH). CKD in PNH is induced mainly by intravascular hemolysis of PNH-affected red blood cells (RBC) missing the glycosylphosphatidylinositol-anchored proteins with complement-regulatory activities, CD55 and CD59. CKD develops by heme absorption in the proximal tubules resulting in the interstitial deposition of iron in the kidneys. We administered eculizumab to a patient with PNH, who was one of 29 patients enrolled in the AEGIS clinical trial, an open-label study of eculizumab in Japan. The patient was complicated by stage 3 CKD with impaired estimated glomerular filtration rate (eGFR), at grade G3b, and had obvious proteinuria (2-3+, 1-2 g/day). In a two-year extension to the 12-week AEGIS study, eGFR improved significantly, and the eGFR has since been maintained at grade G2 without proteinuria by sustained eculizumab treatment (>6 years). Renal function improved and maintained by long-term sustained eculizumab treatment, presumably by clearance of iron from the kidney as well as inhibition of the production of anaphylatoxin C5a, even in advanced stages of CKD, is one of the benefits of eculizumab treatment in PNH.

References

  1. Am J Kidney Dis. 2009 Jun;53(6):982-92 - PubMed
  2. Int J Hematol. 2013 Oct;98(4):406-16 - PubMed
  3. Medicine (Baltimore). 2004 May;83(3):193-207 - PubMed
  4. Blood. 1981 Jan;57(1):83-9 - PubMed
  5. Br J Haematol. 2013 Jul;162(1):62-73 - PubMed
  6. Int J Hematol. 2011 Jan;93(1):36-46 - PubMed
  7. Intern Med. 1993 Sep;32(9):686-90 - PubMed
  8. J Am Soc Nephrol. 2012 Jul;23(7):1229-37 - PubMed
  9. Am J Hematol. 2010 Aug;85(8):553-9 - PubMed
  10. Blood. 1995 Jun 1;85(11):3283-8 - PubMed
  11. Am J Kidney Dis. 2010 Jan;55(1):e1-5 - PubMed
  12. Clin Nephrol. 1993 Jan;39(1):28-31 - PubMed
  13. Am J Med. 1977 Jan;62(1):125-9 - PubMed
  14. N Engl J Med. 2004 Feb 5;350(6):552-9 - PubMed

Publication Types